Navigation Links
PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Date:11/12/2009

combinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague
  • For more information about PharmAthene, please visit www.PharmAthene.com.

    Statement on Cautionary Factors

    Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
    2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
    3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
    4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
    5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
    6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
    7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
    8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
    9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
    10. PharmAthene to Delay Release of Full Year 2007 Financial Results
    11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
    (Date:7/28/2015)... PRUSSIA, Pa. , July 28, 2015 ... Food and Drug Administration has accepted for review the ... recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of ... all primary endpoints. Hemophilia A ... or defective factor VIII; nearly all affected patients are ...
    (Date:7/28/2015)... 2015  Faced with increasing challenges such as ... than symptomatic, the global healthcare industry today is ... of curing or significantly changing the course of ... towards regenerative medicine as a viable alternative. ... human health with the potential to resolve unmet ...
    (Date:7/27/2015)... ... July 27, 2015 , ... This is a ... provides a basic overview of the industry including definitions, classifications, applications and industry ... development trends, competitive landscape analysis, and key regions development status. Development policies and ...
    Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3
    ... toy industry has once again leaked an advance copy of ... (and not-so-good) boys and girls in Madison and Washington may ... not pout and they better not cry if an alert ... after midnight. , , Gov. Jim Doyle: Doyle sparred ...
    ... MADISON, WI - To survive and thrive in a decidedly ... evade the propulsive nature of its intestinal home. , ,Capitalizing ... believe they may have found a way to slow the ... in their delivery and holding out the promise not only ...
    ... - The instant Anca Copaescu, then a second-year MBA in ... 2001 G. Steven Burrill Technology Business Plan Competition, she knew ... winning $10,000 - though the money definitely got her attention. ... to fulfill one of her deepest dreams. "Even as a ...
    Cached Biology Technology:Unwrapping Political Perks for the Holidays 2Unwrapping Political Perks for the Holidays 3Tapeworm's Chemical Trick Could Make Drugs More Effective 2Romanian Student Leverages Burrill Competition to Accomplish Her Dream 2Romanian Student Leverages Burrill Competition to Accomplish Her Dream 3
    (Date:6/24/2015)... 24, 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... Europe accounted for 3,822 of the ...
    (Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
    (Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
    Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
    ... at the Texas Biomedical Research Institute in San Antonio ... of "bad" cholesterol. This discovery could lead to the ... heart disease., "Our findings are important because they provide ... reduce heart disease risk in humans," said Laura Cox, ...
    ... Dr. Philippe Wernet, chemist Prof. Dr. Athina Zouni of Humboldt ... Accelerator Laboratory and Dr. Junko Yano of the Lawrence Berkeley ... In spite of the fact that all aerobic organisms ... Because as part of photosynthesis, green plants, algae, and cyanobacteria ...
    ... predicts their political opinions on economic redistribution, according ... , a journal of the Association for Psychological ... psychological scientists Michael Bang Petersen of Aarhus ... Santa Barbara believe that the link may ...
    Cached Biology News:4 genes indentified that influence levels of 'bad' cholesterol 2Snap shots of 1 of life's central processes 2Political motivations may have evolutionary links to physical strength 2
    ... and, until recently, no readily available affinity chromatography ... methods for IgM purification generally are multi-step, tedious ... all of the major impurities present in IgM ... developed an easy-to-use affinity matrix and buffer system ...
    ... lightweight, the Moticam 2300 camera (MC2300) attaches ... eyetube, or trinocular port. Included in the ... Images 2.0ML software offers quick and accurate ... maximize resolution for examination or documentation purposes. ...
    ... Benzonase is a trademark of Merck KGaA. Physical ... HCl, pH 8.0, 2 mM MgCl 2 , and ... digest sonicated herring sperm DNA to acid-soluble oligonucleotides equivalent ... min at pH 8.0 at 37 C (reaction volume ...
    ... StabilCoat Immunoassay Stabilizer is an aqueous solution ... other non-toxic chemicals in a PBS buffer ... This product does not contain a ... conformation and activity of dried protein components ...
    Biology Products: